Reset filter
Keywords
Obesity ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

106 Search results.
Relevance Rating New first Old first

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1521498 in healthy subjects NCT00857883 - Summary Study conclusion; Ethnicity; Liver Events; Pregnancy Test; Alcohol Breath Test; Drug Screen

- 4/9/20 - 1 form, 8 itemgroups, 56 items, 1 language
Itemgroups: Administrative, Study Completion, Ethnicity, Liver Events, Pregnancy Test, Partner Pregnancy Information, Alcohol Breath Test, Drug Screen
Study ID: 111314 Clinical Study ID: 111314 Study Title: A first-time-in-human, three-part, placebo-controlled, dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1521498 in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00857883 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK1521498 or placebo Study Indication: Obesity

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1521498 in healthy subjects NCT00857883 - Vitals; PK; Dosing; Medications; Concomitant Medication

- 4/8/20 - 1 form, 6 itemgroups, 67 items, 1 language
Itemgroups: Administrative, Vitals, PK, Dosing, Medications - Drug, Concomitant Medication
Study ID: 111314 Clinical Study ID: 111314 Study Title: A first-time-in-human, three-part, placebo-controlled, dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1521498 in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00857883 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK1521498 or placebo Study Indication: Obesity

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1521498 in healthy subjects NCT00857883 - Adverse Events; Demography; Height Weight; ECG

- 4/6/20 - 1 form, 7 itemgroups, 85 items, 1 language
Itemgroups: Administrative, Adverse Events, Serious Adverse Events, Demography, Height Weight, ECG, ECG Holter
Study ID: 111314 Clinical Study ID: 111314 Study Title: A first-time-in-human, three-part, placebo-controlled, dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1521498 in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00857883 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK1521498 or placebo Study Indication: Obesity

Eligibility Obesity NCT02271776

- 3/4/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
GOS and Insulin Sensitivity; ODM derived from: https://clinicaltrials.gov/show/NCT02271776

Eligibility Obesity NCT02453711

- 6/2/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT02453711

Eligibility Obesity NCT02432950

- 6/2/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02432950

Eligibility Obesity NCT02347020

- 6/2/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Impact of Sleep and Meal Timing on Food Intake Regulation; ODM derived from: https://clinicaltrials.gov/show/NCT02347020

Eligibility Obesity NCT02068872

- 6/2/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Gastric Sleeve Pilot Study in Morbidly Obese Undergoing Liver Transplantation; ODM derived from: https://clinicaltrials.gov/show/NCT02068872

Eligibility Obesity NCT02068885

- 6/1/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Framingham State Food Study; ODM derived from: https://clinicaltrials.gov/show/NCT02068885

Eligibility Obesity NCT01693406

- 1/17/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Breast Milk and Infant Growth Among Lean, Overweight and Diabetic Mothers; ODM derived from: https://clinicaltrials.gov/show/NCT01693406

Eligibility Obesity, Morbid NCT00957957

- 1/10/19 - 1 form, 2 itemgroups, 8 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Gut Hormone Profiling in Obese Patients With Type 2 Diabetes (MK-0000-134); ODM derived from: https://clinicaltrials.gov/show/NCT00957957

Eligibility Obesity NCT01974778

- 1/10/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Role for Brown Adipose Tissue in Postprandial Thermogenesis?; ODM derived from: https://clinicaltrials.gov/show/NCT01974778

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial